Amarin Corp Plc (AMRN)

[smarterer]

Hi JL,

You asked

Where did you get the 30% figure for DM in R-I..?

The answer was through deduction, from Dr. Batt's paper from last year. [url][/uhttps://onlinelibrary.wiley.com/doi/full/10.1002/clc.22692rl][tag]Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial[/tag]

The chart near the beginning of Section 2 (Methods) has an initial box titled 'Key Inclusion Criteria' with two categories delineated. First is 'Established CVD' with an annotation that that segment is about 70% of the enrollees. The second category is 'T2DM + >=1 Risk Factor'. I assume T2DM is Type 2 Diabetes Mellitus. What I did not know was whether the first category included diabetics with established CVD. The second category comprised only diabetics; it seemed to me that having a prior MI or other cardiac event would be one type of risk factor. As a result, I deduced that diabetics comprised 30% of the study population at a minimum. If I misread something, and the DM population in the study is higher, that would be great.

Let me know if I missed something, or misunderstood something.

Thanks.

{Edit} Gg just shared JT's numbers from a presentation, so now understand that the population with prior CV events included 20% with diabetes, and 50% without (of the entire trial's 100%). So now have clarity on that. Thanks for raising the question.